Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ). A total of 183 patients with newly diagnosed GBM enrolled in 3 phase II protocols at the Unive...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Polley, Mei-Yin C., Lamborn, Kathleen R., Chang, Susan M., Butowski, Nicholas, Clarke, Jennifer L., Prados, Michael
格式: Artigo
語言:Inglês
出版: Oxford University Press 2010
主題:
Clinical Investigations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940590/
https://ncbi.nlm.nih.gov/pubmed/20167815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop034
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍